| USGOV-DEPARTMENT-OF-DEFENSE |
USGOV-DEPARTMENT-OF-DEFENSE |
95%
|
USAspending awards from Department of Defense: $85,694 across 2 awards. N0018924FZ272 IP2P BRAIN PROBE KITS; N0018925FZ586 IP2P BRAIN PROBE KITS | Qwen corrected direction: Explicit government contra… |
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
95%
|
USAspending awards from Department of Health and Human Services: $88,210 across 1 awards. 75N90025P00591 25-007631 INTEGRA LIFESCIENCES CORPORATION CORDLESS HEADLIGHT SYSTEM AND BATTERIES | Qwen corr… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $651,740 across 7 awards. 36C24625P1066 INTEGRA ULTRASONIC SURGICAL ASPIRATOR SYSTEM; 36C26325P0886 ENT SURGICAL SHAVER; 36C25023P0645 HIGHLY S… |
| MDT |
Medtronic plc |
72%
|
Reciprocal relationship from MDT graph: Reciprocal relationship from IART graph: Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtron… |
| MDT |
Medtronic plc |
72%
|
Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $ 45.0 million. The Company made cash payments … |
| MDXG |
MiMedx Group, Inc. |
72%
|
rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| MDXG |
MiMedx Group, Inc. |
72%
|
Reciprocal relationship from MDXG graph: Reciprocal relationship from IART graph: rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitiv… |
| ORGO |
Organogenesis Holdings Inc. |
72%
|
Reciprocal relationship from ORGO graph: Reciprocal relationship from IART graph: Reciprocal relationship from ORGO graph: Reciprocal relationship from IART graph: rganization, our innovative technol… |
| ORGO |
Organogenesis Holdings Inc. |
72%
|
rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| SMTI |
Sanara MedTech Inc. |
72%
|
Reciprocal relationship from SMTI graph: Reciprocal relationship from IART graph: Reciprocal relationship from SMTI graph: ting room etiquette and credentialing requirements. After completing their i… |
| SNNUF |
Smith & Nephew plc |
72%
|
rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| SNNUF |
Smith & Nephew plc |
72%
|
Reciprocal relationship from SNNUF graph: Reciprocal relationship from IART graph: Reciprocal relationship from SNNUF graph: Reciprocal relationship from IART graph: Reciprocal relationship from SNNU… |
| STE |
STERIS plc |
72%
|
Reciprocal relationship from STE graph: Reciprocal relationship from IART graph: usiness, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical de… |
| STE |
STERIS plc |
72%
|
usiness, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical devices and therapies. Government programs, including Medicare and Medicaid, privat… |
| ARKIS-BIOSCIENCES-INC |
ARKIS-BIOSCIENCES-INC |
62%
|
— $ 13,400 Accrued expenses and other current liabilities Long-Term 7,977 2,557 300 55,300 Other liabilities Total $ 15,755 $ 2,557 $ 300 $ 68,700 F-50 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES… |
| BIOD-LLC |
BIOD-LLC |
62%
|
ts: Research and development (2) Location in financial statements: Selling, general and administrative Arkis BioSciences Inc. As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Compa… |
| DERMA-SCIENCES-INC |
DERMA-SCIENCES-INC |
62%
|
— $ 13,400 Accrued expenses and other current liabilities Long-Term 7,977 2,557 300 55,300 Other liabilities Total $ 15,755 $ 2,557 $ 300 $ 68,700 F-50 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES… |
| FORTIS-ADVISORS-LLC |
FORTIS-ADVISORS-LLC |
62%
|
Three Months Ended March 31, 2025 Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total Total revenue, net $ 280,664 $ 101,989 $ — $ 382,653 Cost of goods sold (1) 10… |
| GENTELL-LLC |
GENTELL-LLC |
62%
|
Acquisition On December 6, 2022, the Company completed its acquisition of Surgical Innovation Associates, Inc. (“SIA”) for an acquisition purchase price of $ 51.5 million (the “SIA Acquisition”) plus… |
| INTEGRA-LIFESCIENCES-HOLDING-CORP |
INTEGRA-LIFESCIENCES-HOLDING-CORP |
62%
|
Three Months Ended March 31, 2025 Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total Total revenue, net $ 280,664 $ 101,989 $ — $ 382,653 Cost of goods sold (1) 10… |
| SURGICAL-INNOVATION-ASSOCIATES-INC |
SURGICAL-INNOVATION-ASSOCIATES-INC |
62%
|
easures. Governmental health systems have revised and continue to consider revisions of healthcare budgets, which could result in stricter standards for implementing certain medical procedures, incre… |
| SURGICAL-INNOVATIONS-ASSOCIATES-INC |
SURGICAL-INNOVATIONS-ASSOCIATES-INC |
62%
|
— $ 13,400 Accrued expenses and other current liabilities Long-Term 7,977 2,557 300 55,300 Other liabilities Total $ 15,755 $ 2,557 $ 300 $ 68,700 F-50 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES… |
| TISSUE-TECHNOLOGIES |
TISSUE-TECHNOLOGIES |
62%
|
al (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately two-thirds of our total revenue, consists of market-leading technologies and instrumentation used for a wide… |
